Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
23. April 2020 08:00 ET | Immunomedics, Inc.
First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...